Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Jean‐Charles Soria(Institut Gustave Roussy), Yi‐Long Wu(Guangdong General Hospital), Kazuhiko Nakagawa(Kindai University), Sang-We Kim(Ulsan College), Jin-Ji Yang(Guangdong General Hospital), Myung‐Ju Ahn(Samsung Medical Center), Jie Wang(Peking University), James Chih‐Hsin Yang(Guangdong General Hospital), You Lü(Sichuan University), Shinji Atagi(NHO Kinki Chuo Chest Medical Center), Santiago Ponce(Hospital Universitario 12 De Octubre), Ki Hyeong Lee(Ulsan College), Yunpeng Liu(First Hospital of China Medical University), Kiyotaka Yoh(National Cancer Centre Japan), Jianying Zhou(Zhejiang University), Xiaojin Shi, Alan Webster(AstraZeneca (United Kingdom)), Haiyi Jiang, Tony Mok(Chinese University of Hong Kong)
Cited by 409
Abstract
Related Papers
No related papers found
Powered by citation graph analysis